By clicking “View Open Positions”, you acknowledge and consent to your personal information being transferred cross-border to Pivotal Headquarters in Hong Kong. For more details, please refer to the Recruitment Privacy Policy.
Our deep resources and industry knowledge make us the ideal partner to scientists and entrepreneurs worldwide.
Pivotal·Family | Zenas与诺诚健华达成逾20亿美元自免管线授权协议，同步增发再获1.2亿美元融资
Pivotal·Family | Zenas BioPharma和Royalty Pharma达成融资协议，最高可达3亿美元
Pivotal夏季回顾 | 碧沃投资本荣登多项榜单，国际化生态持续赋能
Pivotal·Family | Windward宣布启动长效TSLP抗体药物全球 II 期哮喘临床试验
Pivotal·Family | 维昇药业与安科生物达成战略合作 共拓长效生长激素中国市场
三重焕新，启航未来——Pivotal中文品牌发布暨乔迁新址、新官网上线
Pivotal·Family | 合凯维HerResolve全球首发,无创诊断子宫内膜异位症92%准确率获LDT验证
Pivotal bioVenture柳丹博士受邀参加2025中关村论坛年会
Pivotal·Family | 祝贺港股生长发育及内分泌第一股维昇药业成功上市
Pivotal·Family | 极目生物葡萄膜炎性黄斑水肿新药锋脉®/ARCATUS®获澳大利亚新药上市批准
Pivotal bioVenture Partners China Closes Inaugural $150 Million Early Stage VC Fund
Oncologie Launches with 16.5M USD Seed Funding Led by Pivotal bioVenture Partners China
Arctic Vision Announces US$32MN in Series A
Oncologie（鼎航医药）公布最新临床研究数据
Evommune完成1250万美元种子轮融资
OncXerna is selected as Global Top 5 Precision Medicine Startups
Exscientia announces investment of up to $525M
Arctic Vision Received China IND Clearance for Phase III Study of ARVN002 to Reduce Paediatric Myopia Progression
Engrail Therapeutics Extends Series A Financing to $64 Million
QIAGEN and OncXerna Therapeutics Sign Licensing and Master Companion Diagnostic Agreements
SHANGHAI
Suite 2001, YI FUNG PLACE
99 West Ziyun Road
Changning District
Shanghai 200051, China
HONG KONG
17th Floor
AIRSIDE
2 Concorde Road, Kai Tak
Hong Kong SAR
SAN FRANCISCO
501 2nd Street, Suite 200
San Francisco, CA 94107
United States
中文
English
